Search

Your search keyword '"Begna, Kebede"' showing total 859 results

Search Constraints

Start Over You searched for: Author "Begna, Kebede" Remove constraint Author: "Begna, Kebede"
859 results on '"Begna, Kebede"'

Search Results

1. Clonal heterogeneity in STAG2m myeloid neoplasms: the Mayo Clinic experience

4. Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events

5. Abnormal karyotype is an independent predictor of inferior survival in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

7. Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS)

8. Spectrum of clonal hematopoiesis in VEXAS syndrome

9. Autoimmune manifestations in STAG2-mutated myeloid neoplasms

10. A phase 1b/2 study of pivekimab sunirine (PVEK, IMGN632) in combination with venetoclax/azacitidine for patients with newly diagnosed CD123-positive acute myeloid leukemia.

14. Clinicopathologic correlates and prognostic impact of lymphoid aggregates in patients with myelodysplastic syndromes.

15. Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent

19. Bone marrow dendritic cell aggregates associate with systemic immune dysregulation in chronic myelomonocytic leukemia

20. Hybridization capture-based next generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis

21. Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents

22. Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology

23. Genetic landscape and clinical outcomes of patients with BCOR mutated myeloid neoplasms

24. Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival

25. CML and the WHO: Why?

26. TP53 variant allele frequency and therapy‐related setting independently predict survival in myelodysplastic syndromes with del(5q)

27. Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients

29. Molecular markers demonstrate diagnostic and prognostic value in the evaluation of myelodysplastic syndromes in cytopenia patients

31. Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients

33. TP53 variant allele frequency and therapy‐related setting independently predict survival in myelodysplastic syndromes with del(5q).

34. CML and the WHO: Why?

35. Granularity in disease classification impacts survival prediction in advanced systemic mastocytosis: A single institution study of 329 informative cases

37. POSTER: AML-497 Salvage Treatment With Venetoclax (Ven) and Hypomethylating Agents (HMA) for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia (AML) Patients: Clinical Characteristics and Outcomes

38. AML-497 Salvage Treatment With Venetoclax (Ven) and Hypomethylating Agents (HMA) for Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia (AML) Patients: Clinical Characteristics and Outcomes

39. AML-262 Pivekimab Sunirine (PVEK, IMGN632) Triplet With Azacitidine and Venetoclax Shows Broad Activity in Adverse Genetic Subsets of Relapsed/Refractory Acute Myeloid Leukemia and Reduced Infusion-Related Reactions

40. Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation

41. Mayo Clinic experience with 1123 adults with acute myeloid leukemia

43. Molecular predictors of response and survival following IDH1/2 inhibitor monotherapy in acute myeloid leukemia

46. Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival.

47. Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients.

Catalog

Books, media, physical & digital resources